Call Us + 33 1 84 88 31 00

Article R5121-74 of the French Public Health Code

I.-The prescriber’s request for compassionate access authorisation as provided for in II of Article L. 5121-12-1 is sent to the Agence nationale de sécurité du médicament et des produits de santé by electronic means by the pharmacist managing the internal use pharmacy of a healthcare establishment or by the person in charge as referred to in Article L. 5126-10. It includes the following information 1° The name and position of…

Read More »

Article R5121-74-1 of the French Public Health Code

I.- When examining any request for authorisation for compassionate access, the Director General of the Agence nationale de sécurité du médicament et des produits de santé has the prerogatives set out in Article R. 5121-34. II.- As soon as a first request for authorisation for compassionate access for a medicinal product in a specific indication is received, the Director General of the Agence nationale de sécurité du médicament et des…

Read More »

Article D5121-74-1-1 of the French Public Health Code

I.- The maximum value of the period referred to in the second paragraph of II of article L. 5121-12-1 is set at twelve months from the date on which the authorisation referred to in this article is granted. By way of derogation from the previous paragraph, when the indication for which authorisation is sought is a rare disease, the maximum value of the period is increased to eighteen months from…

Read More »

Article R5121-74-2 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé shall refuse authorisation for compassionate access if the conditions laid down in I, II and V of Article L. 5121-12-1 or if the provisions of this section are not complied with, or for any other public health reason.

Read More »

Article R5121-74-3 of the French Public Health Code

I.- Authorisation for compassionate access is granted by the Director General of the Agence nationale de sécurité du médicament et des produits de santé for the duration of treatment of the patient in question, up to a maximum of one year. This authorisation includes: 1° The name and contact details of the prescriber and the contact details of the pharmacy for internal use in the health establishment or of the…

Read More »

Article R5121-74-4 of the French Public Health Code

I.-The compassionate access authorisation may be renewed. Renewal is the subject of a request from the holder of this authorisation addressed to the Director General of the Agence nationale de sécurité du médicament et des produits de santé. This request is accompanied by any clinical data of which the prescriber was aware during the previous authorisation period and a statement from the prescriber attesting to the interest in continuing the…

Read More »

Article R5121-74-5 of the French Public Health Code

I.-The granting of a compassionate access authorisation is subject to the establishment by the Agence nationale de sécurité du médicament et des produits de santé of a therapeutic use and patient monitoring protocol. This protocol specifies in particular the indication concerned, the dosage, the conditions of prescription and dispensing, the obligations relating to pharmacovigilance and, where applicable, the monitoring data relating to efficacy and safety and the conditions of use…

Read More »

Article R5121-74-6 of the French Public Health Code

Where the therapeutic use and patient monitoring protocol so provides, the holder of the exploitation rights for a medicinal product benefiting from a compassionate access authorisation or, where applicable, his authorised representative, sends the Director General of the Agence nationale de sécurité du médicament et des produits de santé, at intervals established by the protocol, a report called a “periodic summary report”. This report includes in particular: 1° A summary…

Read More »

Article R5121-74-7 of the French Public Health Code

In order to be able to continuously assess the benefit/risk balance of the medicinal product, the Director General of the Agence nationale de sécurité du médicament et des produits de santé may at any time request the holder of the marketing rights for the medicinal product which is the subject of the compassionate access authorisation or, where applicable, its authorised representative, to provide it without delay with data enabling it…

Read More »

Article R5121-74-8 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé may suspend or withdraw a compassionate access authorisation if the conditions laid down in I, II and V of Article L. 5121-12-1 or the provisions of this section are not complied with, or for any other public health reason. Except in cases of urgency, suspension or withdrawal may only take place after the authorisation…

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.